In summary, during the last decade by far the most remarkable gain has become achieved in HER2/neu-overexpressing MBC. Introduction of bevacizumab like a VEGF-directed targeted therapy continues to be an issue on debate. A number of the novel therapeutics to your breast cancer armamentarium resu